Please ensure Javascript is enabled for purposes of website accessibility

Bioscience organization to host inaugural conference on Isle of Palms

Staff //February 24, 2020//

Bioscience organization to host inaugural conference on Isle of Palms

Staff //February 24, 2020//

Listen to this article


Southeast Life Sciences will host its inaugural Advanse Life Sciences Conference this spring on the Isle of Palms.

The conference is scheduled for May 28-29 at the Wild Dunes Resort. It will highlight innovations from 50 early stage medical technology and bioscience companies.

The Lowcountry was chosen to host the inaugural conference because the region has the capacity to accommodate the anticipated 500 participants, and because it is easy for stakeholders in places such as Florida, Atlanta and Nashville to access, according to Southeast Life Sciences spokesman Paul Snyder.

Southeast Life Sciences is a new organization born out of a merger of the Southeastern Medical Device Association and Southeast BIO. It provides a platform for biopharma, medical device, diagnostics and digital health industries to connect with investors, potential partners and other resources. In the past, the two organizations operated as sister organizations.

“The convergence of medical technologies, including devices, with bioscience technologies including drugs, data, digital and combination products necessitates the convergence of these entities,” Southeast Life Sciences Executive Director Jason Rupp said. “In order to respond to the combined needs of stakeholders in both ecosystems, the time has arrived for SEBIO and SEMDA to come together under one roof.”

Snyder said the organization is made up of a combination of industry people from public and private companies, economic development representatives, higher education professionals, researchers and regulatory experts, among others.

He said these people need to be connected because it takes many stakeholders to translate discovery from the lab through regulatory processes to manufacturing and commercialization.

“With the advent of devices like CardioMems (a wireless heart failure monitor) that blend device data and devices that deliver pharmaceutical therapies, close connectivity between medical device and bioscience innovators is advantageous to regional stakeholders, especially investors,” Rupp said.